Description：Clazosentan (Ro 61–1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction[1][5].
In Vitro：Clazosentan (0.1 μM) inhibits the ETA receptor in cerebral arteries[3].
Clazosentan is a substrate of the organic anion-transporting polypeptide (OATP) 1B1/1B3[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clazosentan Related Antibodies
In Vivo
Clazosentan (10 μM, 0.05 mL/kg, intracisternal injection) inhibits the contractile responses to ET-1 in rats[2].
Clazosentan (10 mg/kg, s.c.) inhibits IL-33-induced hypernociception in mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:Rats[2]Dosage:10 μM, 0.05 mL/kgAdministration:Intracisternal injectionResult:Inhibited the contractile responses to ET-1, without preventing SAH-induced upregulation of ET receptors in cerebral arteries.